gastrointestinal endoscope News
-
New Research Shows Progression to Esophageal Cancer as Detected by WATS3D
A newly published study as lead article in Gastrointestinal Endoscopy shows that Barrett’s esophagus (BE) and dysplasia progress to esophageal cancer at similar, or even higher, rates when diagnosed by WATS3D (wide-area transepithelial sampling with three-dimensional analysis) as they do when diagnosed by conventional forceps biopsies. This study titled “Progression of ...
-
Avalon Healthcare Solutions’ Client BCBS of South Carolina Adds CDx Diagnostics as In-Network Lab
CDx Diagnostics, Inc. is pleased to announce that it has signed an agreement with laboratory benefits management provider Avalon Healthcare Solutions, Inc. of Tampa, Fla. The agreement means that CDx will be an in-network specialty anatomic pathology laboratory of Avalon client BlueCross BlueShield of South Carolina, and builds on Avalon’s positive medical policy for CDx’s proprietary ...
-
CDx Diagnostics’ WATS3D Receives “Medically Necessary” Designation from Highmark Health Plans
WATS3D, a diagnostic platform developed by CDx Diagnostics to empower physicians to detect Barrett’s esophagus (BE) and esophageal dysplasia, has been designated as medically necessary by Highmark Blue Cross Blue Shield plans in Delaware, Pennsylvania, and West Virginia. Clinically proven to significantly increase the detection rate of BE, pre-cancer, and cancerous cells in the esophagus ...
-
CDx Diagnostics’ WATS3D Participates in Highmark, Inc. Health Plans in Delaware, Pennsylvania, and West Virginia
WATS3D, an AI powered diagnostic platform developed by CDx Diagnostics to empower physicians to reliably detect Barrett’s esophagus (BE) and esophageal dysplasia to help prevent esophageal cancer, was designated as medically necessary by Highmark, Inc. health plans in Delaware, Pennsylvania, and West Virginia in Q4 2021. CDx Diagnostics is pleased to share, that effective immediately, ...
-
University Hospitals Ventures to Expand Collaboration with Lazurite™ and Invest in the Company
Medical device and technology company Lazurite Holdings LLC today announced a new phase of collaboration with University Hospitals (UH) Ventures, the innovation and commercialization arm of University Hospitals Health System in Cleveland, which will include an investment from UH Ventures. The amount and details of the investment were not specified. This past August, Lazurite announced its ...
-
Medical Device Company Lazurite™ Named a 2021 Top 10 Endoscopy Device Provider by MedTech Outlook Magazine
Medical device and technology company Lazurite Holdings LLC has been recognized by MedTech Outlook magazine as a 2021 Top 10 Endoscopy Device Provider for its ArthroFree™ wireless camera system for minimally invasive surgery. MedTech Outlook describes itself as a platform that bridges the spectrum between medtech technology providers and healthcare facilities and medical institutes. In ...
-
Palisade Bio (Nasdaq: PALI) To Present New Clinical Data Of LB1148 For Preventing Adhesions In Conjunction With Next Big Thing Session At Society Of American Gastrointestinal And Endoscopic Surgeons 2022 Annual Meeting
Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, was selected to present an ePoster entitled “Pooled-Analysis of Incidence and Severity of Post-Surgical Intraabdominal Adhesions following Bowel Resection Surgery and Treatment with Enteral Protease Inhibitor LB1148” at The Next ...
By Palisade Bio
-
Lazurite™ Announces FDA 510(k) Submission for its ArthroFree™ Wireless Camera System; is Recognized by AngelMD as One of the Best Startups of 2021
Medical device and technology company Lazurite Holdings LLC today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its ArthroFree™ wireless camera system for minimally invasive surgery, and that the submission has been accepted for review. The company also announced that early-stage healthcare investment platform AngelMD named it ...
-
Palisade Bio (Nasdaq: PALI) Announces Analysis Demonstrating LB1148 Reduced The Extent And Severity Of Post-Surgical Intraabdominal Adhesions By 93%
Data from Pooled-Analysis of Enteral Protease Inhibitor LB1148 Demonstrated 72% Reduction in the Risk of Adhesion Formation in Patients Undergoing Bowel Resection Surgery Company to Host Conference Call on Wednesday, March 16, 2022, at 8:30 a.m. EST Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) ...
By Palisade Bio
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you